In our study, we have demonstrated that 5-HT1A agonism and 5-HT2A antagonism can act as monotherapies in tackling the core symptoms of ADHD by indirectly modulating DA neuroreceptor activity. The gene discussed is HTR2A; the disease is attention deficit-hyperactivity disorder.